Third Harmonic pushes IPO window open with inflammation drug from Novartis
Third Harmonic Bio, which emerged from stealth early this year with a lead drug from Novartis and a $105 million round of funding, has not yet set any financial terms for its planned IPO. But the biotech plans to use the IPO cash for early and mid-stage clinical tests of its small molecule in multiple inflammatory indications.